Authors of articles accepted for publication will be asked to pay article processing charges on the basis of publication license and their ASN membership status as follows—standard CCBY-NC license, ASN nonmember: $2,000; standard CCBY-NC license, ASN member: $1,800; CCBY license, ASN nonmember: $3,300; CCBY license, ASN member: $3,000.
Authors will be billed for the costs of corrections or changes after manuscript acceptance at the rate of $4.00 per occurrence unless they are to correct errors due to editorial, redactory, or printing services.
Authors who lack funding for payment can request a waiver of the author processing charges. Requests for waivers must be signed by the corresponding author and cosigned by an appropriate institutional official to verify that no institutional or grant funds are available for the payment of the fee. Please include the manuscript title and the manuscript ID number with your request. Waiver requests should be sent to: American Society for Nutrition, 9211 Corporate Blvd, Suite 300, Rockville, Maryland 20850. Tel: 240-428-3616. Email: email@example.com. Any manuscript for which the article processing charge is waived will be published under CDN's standard CCBY-NC license.
For more information on supplement fees, please contact Sarah McCormack, American Society for Nutrition, 9211 Corporate Blvd., Suite 300, Rockville, MD 20850. Phone: 240-428-3616; e-mail: firstname.lastname@example.org.
All works published in CDN are published under either the Creative Commons CCBY-NC license or CCBY license is mandated. It is the responsibility of authors to inform ASN if the CCBY license is required to satisfy the open access publication requirements of the funding sources pertaining to their manuscripts. All authors must read and sign CDN’s Publishing Agreement (11) and should submit the completed form as soon as possible and as instructed on the footer of the form. As recommended by the Council of Science Editors, when a coauthor dies or is incapacitated during the writing, submission, or peer review process, coauthors should obtain disclosure and copyright documentation from a familial or legal proxy (12). Revised manuscripts will not be processed until the completed form is received from each author.
Where legally and ethically possible, CDN encourages authors to make data supporting their research available to other researchers. Data is most discoverable and useful when deposited in a discipline-specific or a general repository. General subject repositories that are free to authors include Dryad and figshare. Include the DOI of data deposits relevant to your research as a footnote to the manuscript title. Supporting data may also be published with the manuscript as supplemental material.
A Change in Authorship Form (2) must be submitted if:
- an author’s name is added to the manuscript,
- there is a change in the author order, or
- an author wishes to remove his/her name; a letter requesting the removal of his/her name and signed by the author must accompany the form.
Authors are responsible for obtaining permission to adapt or reproduce any copyrighted material requiring this and submitting the written permission with the Publishing Agreement (11). Tables or figures adapted or reproduced from another source must acknowledge that source in a table footnote or the figure legend and be accompanied by written proof that the copyright bearer has granted permission to reproduce or adapt the table or figure.
Papers will be screened for similarity to previously published papers using iThenticate.
Those with disproportionate similarity to published papers will, at the Editor's discretion, be rejected outright or returned to authors for rewriting followed by re-review before a final decision is made.
The following are considered inappropriate re-use of material (plagiarism):
1. Copying the published words of other authors or modifying only slightly, with or without citation of the original work.
2. Reusing the author's own previously published words, with or without citation (self-plagiarism).
3. Failure to quote and/or acknowledge by citation substantially similar ideas, content, tables, or illustrations that have been published or copyrighted by others.
Most published work is copyrighted. Thus, all text in the submitted paper must be original, including the Methods section. Frequently, the previous publication can be cited and thereby the length of the Methods section can be reduced. Review articles also must be original; they cannot repeat verbatim or include only minimally changed words from previous reviews or original research papers by the author or others. The NIH’s Office of Scientific Integrity’s piece, “Avoiding Plagiarism, Self-Plagiarism, and Other Questionable Writing Practices: A Guide to Ethical Writing” (13) is highly recommended.
Individuals who are asked to review a manuscript should decline the solicitation if they have a conflict of interest. Detailed guidelines on conflicts of interest for reviewers can be found at ASN Journals Conflict of Interest Guidelines (5).
Protocol: Reports of human studies must include a statement that the protocol was approved by the appropriate institutional committee or that it complied with the Helsinki Declaration as revised in 1983.
Clinical Trials: Registration is required for all clinical trials that began after July 1, 2010. When preparing reports of randomized, clinical trials, refer to the checklist published in the CONSORT Statement (14). Include a CONSORT flow diagram as a manuscript figure summarizing participant flow with the sizes (n) of initial (recruited, enrolled) and final groups. Indicate in both the abstract and the manuscript text whether the outcomes reported are primary or secondary outcomes of the study.
Systematic reviews and meta-analyses: For systematic reviews and meta-analyses, refer to the PRISMA checklist and include a PRISMA flow diagram as a figure in the manuscript (15).
Animal research: Research on animals should include a statement that the protocol was approved by the appropriate committee or complied with the Guide for the Care and Use of Laboratory Animals (16). Compliance with the ARRIVE guidelines is encouraged (17). Describe how animals were euthanized. Describe control and experimental animals or participants, giving age, weight, sex, race, and for animals, breed or strain. Include the supplier of experimental animals.
Health research reporting checklists: CONSORT, PRISMA, and ARRIVE checklists can be uploaded as supplemental material for the benefit of reviewers and editors.
Composition of control and experimental diets must be presented. When a diet composition is published for the first time in CDN, provide complete information on all components in a table. If previously described in CDN, JN, or AJCN, a reference may be used. State specifically any modifications made to the published diet compositions. The proximate composition of closed formula diets should be given as amounts of protein, energy, fat, and fiber. Express components as g/kg diet. Vitamin and mineral mixture compositions should be included using CDN units and nomenclature. For a discussion of the formulation of purified animal diets, refer to Baker (18) and to a series of ASN publications (19–22). The experimental diets should differ from the control diets only in the nutrient(s) being investigated. Nonpurified diets generally should not be used as control diets; animals fed these diets should be included for reference only and their data should not be included in the statistical analysis.
Describe all statistical tests utilized and indicate the probability level (P) at which differences were considered significant. If data are presented in the text, state what they represent (e.g., mean ± SEM). Indicate whether data were transformed before analysis. Specify any statistical computer programs used.
Present the results of the statistical analysis of data in the body of each table and on figures per se. Use letters or symbols to indicate significant differences; define these in a table footnote or the figure legend. Provide the appropriate statistics of variability with an estimate of the error variance (SD or SEM) of group means. Standard ANOVA methodology assumes a homogeneous variance. If error variance is tested and found to be heterogeneous, transform data before ANOVA, or use nonparametric tests. For a discussion of variability calculations and curve-fitting procedures, see Baker (18).
If non-significant P values are reported, use only 2 digits past the decimal (e.g., P=0.15). Present significant P values to a maximum of 4 decimal places (e.g., P<0.0001); using fewer is acceptable. Present coefficients to a maximum of 2 decimal places (e.g., r=0.87, R2=0.16, etc.).
Metric units are required (e.g., m, kg, and L for height, weight, and volume, respectively), as is the Celsius scale (°C). For reporting data, use of SI units (le Systeme Internationale d’Unites) (23) is preferred (e.g., mmol/L, g/L) but not mandatory. Conventional units such as mg/dL and mg/mL are acceptable, using L, not l, for liter. Use units for the same analyte/compound consistently throughout the manuscript. Placing an alternate unit parenthetically in the text or giving conversion factors in table footnotes or figure legends is acceptable. Units should not be pluralized (e.g., wk, not wks) or followed by a period.
Useful websites are:
SI conversions: http://www.onlineconversion.com/
SI conversions: http://en.wikipedia.org/wiki/Conversion_of_units
Clinical SI conversions: http://dwjay.tripod.com/conversion.html
Chemical and biochemical terms and abbreviations and identification of enzymes generally should conform to the recommended usage of the International Union of Biochemistry and Molecular Biology (24). Names for vitamins, related compounds, and abbreviations for amino acids should follow the ASN nomenclature policy (25, 26).
For fatty acids, use the ω or n system consistently with a colon to separate the chain length and number of bonds (e.g.,18:2n–6, 20:5n–3, 18:2ω-6, 20:5ω-3). In the text, refer to n–3 fatty acids, ω3 PUFA, the ratio of n–3/n–6 fatty acids, etc. Regardless of which system is used in the text, include the alternative form in parentheses in the abstract.
Use common names and systematic names together at first mention, and then use the common name throughout. In general, there is no need to use the abbreviations “c” and “t” to denote cis and trans after first usage [e.g., cis-9, trans-11 CLA (18:2c9,t11)]. If, however, the article includes many references to systematic names including cis and trans designators, it may be more economical to use the “c” and “t” designators.
Full gene names are not required for tables and figures in which a database identifier number is given. A full citation to the database used should be in the References and the sequential reference number to the citation provided in the text, figure legend, or table footnote. If the genes are listed in supplemental material, the citation can be given as a table footnote or in the figure legend [e.g., National Center for Biotechnology Information (NCBI) Gene (27) or Unigene (28)].
All gene symbols should be italicized throughout the text, tables, and figures. The use of prefixes to designate species is not allowed. For rodent genes, the first letter should be uppercase with the rest in lowercase letters (e.g., for PPARγ, Pparg). For human genes, all letters should be uppercase (e.g., PPARG). Messenger RNA (mRNA) and complementary DNA (cDNA) use the same gene symbol and formatting conventions. Protein designations are the same as the gene symbols, are in all uppercase letters (even rodents), and are not italicized (e.g., PPARG). For the genes of other species, follow the convention for abbreviating human gene and protein names. Further information on gene and protein nomenclature rules can be found as indicated in the list below.
Human: HUGO Gene Nomenclature Committee (HGNC) (29)
Mouse: Mouse Genome Nomenclature Committee (MGNC) (30)
Rat: Rat Genome and Nomenclature Committee (RGNC) (31)
Bovine: Bovine Genome Database (BGD) (32)
Chicken and other avians: Chicken Gene Nomenclature Committee (CGNC) (33)
Xenopus and other amphibian (34)
Zebrafish and other piscine: Zebrafish Model Organism Database (ZFIN) (35)
Porcine: No official genome nomenclature committee statements or annotation resources are available online to date. The International Society for Animal Genetics (ISAG) publishing guidelines defer to the HUGO Name (29) when applicable. Use NIH Gene (27) or HUGO (29) to confirm names. Where one-to-one human orthology cannot be established, an unofficial gene symbol can be used if it is supported by a previous literature assignment. Clade-specific or species-specific genes will be designated with an official gene symbol upon completion of the genome.
Equine, ovine, canine: No official genome nomenclature committee statements or annotation resources are available online to date; see porcine guidelines.
With respect to defining gene and protein symbols, please follow the instructions in the list below.
1. Text: Define all gene and protein symbols (abbreviations) at first use in the abstract and text.
2. Tables and figures: Define protein symbols or abbreviations. Full gene names are not required for tables and figures in which a database identifier number is given. Therefore, either use NM_ or other database identification numbers or define gene symbols.
3. Abbreviation footnote: Define protein symbols (abbreviations). Do not define genes for which a database identifier number is given in the text, tables, or figures. Define gene names for which a database identifier number is not given.
Use standard abbreviations in CDN papers without definition in the text. Standard abbreviations, however, should be defined at first mention in the abstract. An abridged list is in Table 1 (37). Other common standard abbreviations are listed in Scientific Style and Format (12).
Each nonstandard (author-defined) abbreviation should be defined in the abstract and text at first mention. If three or more nonstandard abbreviations are used in the text, prepare an abbreviation footnote. The footnote should be associated with the first abbreviated term in the text and should be an alphabetized listing of all author-defined abbreviations and their definitions. Group designations should be defined parenthetically at first mention [for example, “control (CON) and high-fat (HF) groups”] and included in the abbreviation footnote. Abbreviations (other than units such as min, h, m, kg) should be pluralized where appropriate (e.g., The n-3 PUFAs are…) but should not be followed by a period. Use the standard abbreviations for SI prefixes found in Young (29) and in Table 2 and those for units of measure in Table 3 (38).
All nonstandard abbreviations, including group or treatment designations, used in a table or table title must be defined alphabetically in a footnote to the table title. If the footnote to the table title contains multiple items, the definitions of the abbreviations should be the last item. If a table contains only one abbreviated term in the body of the table, then a separate footnote placed after that abbreviation should be used to define that term. Similarly, all nonstandard abbreviations, including group or treatment designations, used in a figure or figure legend must be defined alphabetically at the end of the figure legend.
Last updated November 2, 2016